Cost-effectiveness analysis of thiazolidinediones in uncontrolled type 2 diabetic patients receiving sulfonylureas and metformin in Thailand

Value in Health

Volumn 11, Issue SUPPL. 1, 2008, Pages

  Chirakup, Suphachai ^a,b   Chaiyakunapruk, Nathorn ^a,c,d   Chaikledkeaw, Usa ^c,e   Pongcharoensuk, Petcharat ^e   Ongphiphadhanakul, Boonsong ^f   Roze, Stephane ^g   Valentine, William J ^g   Palmer, Andrew J ^g  

^a NARESUAN UNIVERSITY   (Thailand)

^b PAYAP UNIVERSITY   (Thailand)

^c MINISTRY OF PUBLIC HEALTH   (Thailand)

^d UNIVERSITY OF QUEENSLAND   (Australia)

^e MAHIDOL UNIVERSITY   (Thailand)

^f MAHIDOL UNIVERSITY   (Thailand)

^g IQVIA   (United States)

Author keywords

Cost effectiveness analysis; Pioglitazone; Rosiglitazone; Thiazolidinediones

Indexed keywords

GLITAZONE DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE;

ADULT; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DEATH; DECISION MAKING; DIABETIC PATIENT; DRUG EFFICACY; DRUG FORMULARY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MALE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RENAL REPLACEMENT THERAPY; THAILAND; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION;

EID: 41749116887     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2008.00366.x     Document Type: Conference Paper

References (40)

1. King H, Aubert R, Herman W. Global Burden of Diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998 21 : 1414 31.
2. Aekplakorn W, Cheepudomwit S, Stolk RP, et al. The prevalence and management of diabetes in Thai adults. Diabetes Care 2003 26 : 2758 63.
3. Health Systems Research Institute. Diabetes registry project, 2003. Available from: http://library.hsri.or.th/cgi-bin/websis?from=res1&show= 802&with=diabetes%20registry%20project [Accessed April 2007].
4. Yacg D, Hawkes C, Gould LC, et al. The Global burden of chronic diseases: overcoming impediments to prevention and control. JAMA 2004 291 : 2616 22.
5. Wake N, Hisashige A, Katayama T, et al. Cost-effectiveness of intensive insulin therapy for type 2 diabetes: a 10-year follow-up of the Kumamoto study. Diabetes Res Clin Prac 2000 48 : 201 10.
6. O'Brien JA, Patrick AR, Caro J. Estimates of direct medical costs for microvascular and macrovascular complications resulting from type 2 diabetes mellitus in the United States in 2000. Clin Ther 2002 25 : 1017 38.
7. UKPDS Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998 352 : 837 53.
8. van Wijk JP, de Koning EJ, Martens EP, et al. Thiazolidinediones and blood lipids in type 2 diabetes. Arterioscler Thromb Vasc Biol 2003 23 : 1744 9.
9. Dormandy JA, Charbonnel B, Eckland DJA, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (prospective pioglitazone clinical trial in macrovascular event): a randomized controlled trial. Lancet 2005 366 : 1279 89.
10. Vondeling H, Iversen PB. Reimbursement of glitazones in treatment of type 2 diabetes patients in Denmark in the context of a voluntary system for submitting pharmacoeconomic studies. Eur J Health Econ 2004 5 : 263 9.
11. Neeser K, Lubben G, Siebert U, et al. Cost effectiveness of combination therapy with pioglitazone for type 2 diabetes mellitus from a German statutory healthcare perspective. PharmacoEconomics 2004 22 : 321 41.
12. Henriksson F. Applications of economic models in healthcare: the introduction of pioglitazone in Sweden. PharmacoEconomics 2002 20 : 43 53.
13. Plosker GL, Figgitt DP. Repaglinide: a pharmacoeconomic review of its use in type 2 diabetes mellitus. PharmacoEconomics 2004 22 : 389 411.
14. Czoski-Murray C, Warren E, Chilcott J, et al. Clinical effectiveness and cost-effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes: a systematic review and economic evaluation. Health Technol Assess 2004 8 : 1 91.
15. Veenstra DL, Ramsey SD, Sullivan SD. A guideline for the use of pharmacoeconomic models of diabetes treatment in the US managed-care environment. PharmacoEconomics 2002 20 : 21 30.
16. Palmer AJ, Roze S, Valentine WJ, et al. The CORE diabetes model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin 2004 20 (Suppl. S5 26.
17. Chiquette E, Ramitrez G, DeFronzo R. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med 2004 164 : 2094 104.
18. Drug Medical Supply and Information Center (DMSIC) ministry of public health Thailand. Available from: http://dmsic.moph.go.th/price/price1.php [Accessed January, 2006].
19. Exchange rate by bank of Thailand. Available from: http://www.bot.or.th/ bothomepage/index/index_e.asp [Accessed April, 2007].
20. Health Information Group, Bureau of Health Policy and Strategy Ministry of Public Health Thailand. Number of ages-sex specific death rate per 1,000 population. 2004. Available from: http://203.157.19.191/input_bps.htm [Accessed January 2005].
21. Krairitichai U, Supaporn T, Lakayanon S, et al. Thailand registry of renal replacement therapy. J Nephrol Soc Thailand 2003 9 : 210 25.
22. Tan-Torres Edejer T, Baltussen R, Adam T, eds. Making Choices in Health: WHO Guide to Cost-Effectiveness Analysis. Geneva : World Health Organization, 2003.
23. Diabetes Control and Complications Trial/;Epidemiology of Diabetes Interventions and Complication (DCCT-EDIC) Research Group. Intensive diabetes treatment and cardiovascular disease in patients with Type 1 diabetes. N Engl J Med 2005 353 : 2643 53.
24. The World Health Organization (WHO). Cost-effectiveness thresholds. (2000 International $); by Region. Available from: http://www.who.int/choice/ costs/CER_thresholds_regions.xls [Accessed June 2006].
25. WHO Commission on Macroeconomic and Health. Macroeconomics and Health: Investing in Health for Economic Development. Geneva : World Heatlh Organiazation, 2001.
26. Eichler HG, Kong SX, Gerth WC, et al. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health 2004 7 : 518 28.
27. Palmer AJ, Brandt A, Gozzoli V, et al. Outline of a diabetes disease management model: principles and applications. Diabetes Res Clin Pract 2000 50 (Suppl. S47 56.
28. Kunaratanapruk S. Medical Care Price Schedules for Road Traffic Accidents: The Thai DRG for Accidents. Phitsanulok : Centre for Health Equity Monitoring, 1995.
29. Drummond MF, O'Brien BJ, Stoddart GL, et al. Methods for the Economic Evaluation of Health Care Programmes (2nd ed.). Toronto : Oxford University Press, 1997.
30. Palmer AJ, Roze S, Valentine WJ, et al. Validation of the CORE diabetes model against epidemiological and clinical studies. Curr Med Res Opin 2004 20 : S27 4.
31. Teerawattananon Y. Cost-effectiveness and cost-utility analysis of renal replacement therapy in Thailand. In : Tancharoensathien V, Kasemsap V, Teerawatananon Y, et al., eds. Universal Access to Renal Replacement Therapy in Thailand: A Policy Analysis. Bangkok : International Health Policy Program & Nephrology Society of Thailand, 2005.
32. Health Promotion Foundation Thailand. Alcohol consumption in Thailand. 2003. Available from: http://www.thaihealth.or.th/content.php?SystemModuleKey= situationalcohol&id=2840 [Accessed January 2006].
33. National Statistical Office. Tobacco and alcohol consumption in Thai population 2004. Available from: http://service.nso.go.th/nso/data/data23/ stat_23/toc_4/4.4-5-47.xls [Accessed January 2006].
34. Sriratanasathavorn C, Bhuripanyo K, Nahanonda N, et al. The prevalence of left ventricular hypertrophy and associated factors in a Thai population. J Med Assoc Thai 2000 83 (Suppl. S218 22.
35. Nitiapinyasakul N, Nitiapinyasakul A. Diabetic retinopathy screening in community hospitals. Thai J Ophthalmol 2004 18 : 103 10.
36. Pongchaiyakul C, Tandhanand S. Improvement of diabetes care at Maharat Nakhon Ratchasima hospital: the study of diabcare-Asia from 1997 to 2003. J Med Assoc Thai 2006 89 : 56 62.
37. Pornpinatepong S. Cost-Effectiveness Analysis of Diabetic Retinopathy Screening in Type 2 Diabetes Mellitus. Bangkok : Pharmacy Mahidol University 2005.
38. Tisayathikom K, Patcharanarimon V, Mukem S, et al. Cost and efficiency of public and private hemomialysis centers in 2001. Bangkok : International Health Policy Program, 2003.
39. Tangcharearnsatien V, Terawatananon Y, Kasamsub V, et al. The policy analysis of renal replacement therapy for end stage renal disease patients in basic care package of universal health insurance in Thailand. Thai Med Counc Bull 2001 30 : 215 26.
40. National Health Security Office Thailand. Thai DRGs, Version 3. Bangkok : National health security office Thailand, 2002.